Biotech Stock Roundup: BBIO Stock Up on Drug Approval, SAVA, APLT Plunge on Setbacks & More
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/90.BMDkfsfZ.js ...
HC Wainwright Boosts BridgeBio Pharma (NASDAQ:BBIO) Price Target to $49.00
BridgeBio Pharma (NASDAQ:BBIO – Free Report) had its target price upped by HC Wainwright from $43.00 to $49.00 in a research ...
Research Analysts Set Expectations for BBIO FY2027 Earnings
Equities research analysts at Leerink Partnrs cut their FY2027 EPS estimates for shares of BridgeBio Pharma in a research ...
BridgeBio Stock Up on FDA Approval of Cardiovascular Drug
BBIO gets a significant boost with the FDA approval of acoramidis for the treatment of adults with transthyretin amyloidosis cardiomyopathy. Stock rises.
Zacks.com on MSN4d
FDA Begins Review of Alnylam's sNDA for Expanded Amvuttra Use
Alnylam Pharmaceuticals ALNY announced that the FDA has accepted its supplemental new drug application (sNDA) seeking the ...
BioWorld4d
Bridgebio, with FDA approval, faces Pfizer in ATTR
With the U.S. FDA approval of Attruby (acoramidis) for transthyretin amyloidosis with cardiomyopathy (ATTR-CM), Bridgebio Pharma Inc. is taking on an industry giant. The next-generation, oral, ...
BridgeBio Pharma (BBIO) Receives a Buy from Cantor Fitzgerald
In a report released on November 23, Joshua Schimmer from Cantor Fitzgerald maintained a Buy rating on BridgeBio Pharma (BBIO – Research ...
BridgeBio Pharma (BBIO) Receives a Buy from Piper Sandler
In a report released today, Biren Amin from Piper Sandler maintained a Buy rating on BridgeBio Pharma (BBIO – Research Report), with a price ...
Crude Oil Down 3%; Chicago Fed National Activity Index Falls In October
European shares were higher today. The eurozone's STOXX 600 gained 0.16%, Germany's DAX gained 0.49% and France's CAC 40 rose ...
Newsable Asianet News on MSN5d
BridgeBio Stock Hits 2-Month Highs After Analysts Cheer FDA Nod For Heart Drug: Retail Excitement Builds
BridgeBio Pharma Inc. ($BBIO) stock surged 28% on Monday morning, hitting highs last seen in mid-September, after the company ...
BridgeBio Pharma, Rigetti Computing, Bath & Body Works And Other Big Stocks Moving Higher On Monday
On Friday, the FDA approved BridgeBio Pharma's Attruby (acoramidis), an orally-administered near-complete (≥90%) stabilizer ...
bovnews5d
BridgeBio’s (BBIO) FDA Approval Sparks Surge in Stock Price—What’s Next?
(BBIO), the company announced that its innovative drug, Attruby (acoramidis), has received FDA approval for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM). This approval, granted by ...